drugset / Trial / NCT02372383
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
Completed
31 enrolled
University of Colorado, Denver
Colorado Clinical & Translational Sciences Institute · collabCystic Fibrosis Foundation · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
Timeline
- Start
- 2014-10
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 10 mg/kg | Oral |
| Subject | Ethambutol | Small molecule | 15 mg/kg | Oral |
| Subject | Rifampin | Small molecule | 10 mg/kg | Oral |
| Background | Pancrelipase | Protein / enzyme biologic | — | — |